StreetInsider.com News Articles

Form 6-K PURPLE BIOTECH LTD. For: Jun 23

Tue, 23 Jun 2026 09:29:00 -0400

si-local-file:///var/storage/secattach/20260623/26677181.html

Form 6-K PURPLE BIOTECH LTD. For: Jun 23

Tue, 23 Jun 2026 09:29:00 -0400

si-local-file:///var/storage/secattach/20260623/26677181.html

Form 6-K PURPLE BIOTECH LTD. For: Jun 23

Tue, 23 Jun 2026 09:29:00 -0400

si-local-file:///var/storage/secattach/20260623/26677181.html

Form 6-K PURPLE BIOTECH LTD. For: Jun 11

Thu, 11 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26632495.html

Form 6-K PURPLE BIOTECH LTD. For: Jun 11

Thu, 11 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26632495.html

Form 6-K PURPLE BIOTECH LTD. For: Jun 11

Thu, 11 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260611/26632495.html

Purple Biotech presents IM1240 preclinical data at EACR conference

Thu, 11 Jun 2026 07:01:09 -0400

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) presented preclinical data for its lead candidate IM1240 at the European Association for Cancer Research 2026 Annual Congress held June 8-11 in Budapest, Hungary.

The company reported results from a non-human primate toxicology study showing IM1240 demonstrated an 8-fold longer half-life and 16-fold greater exposure compared to a non-capped variant. The study found IM1240 induced minimal cytokine release at 10 mg/kg dose, while the non-capped version triggered robust cytokine release at 0.03 mg/kg.

In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment

Purple Biotech presents IM1240 preclinical data at EACR conference

Thu, 11 Jun 2026 07:01:09 -0400

In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment

Purple Biotech presents IM1240 preclinical data at EACR conference

Thu, 11 Jun 2026 07:01:09 -0400

In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment

Purple Biotech presents IM1240 preclinical data at EACR conference

Thu, 11 Jun 2026 07:01:09 -0400

In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment

Purple Biotech presents IM1240 preclinical data at EACR conference

Thu, 11 Jun 2026 07:01:09 -0400

In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment

Purple Biotech presents IM1240 preclinical data at EACR conference

Thu, 11 Jun 2026 07:01:09 -0400

In patient-derived tumor samples from head and neck, bladder, and lung cancers resistant to PD-1 therapy and chemotherapy, IM1240 showed anti-tumor activity. The treatment

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Thu, 11 Jun 2026 07:00:00 -0400

Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant

IM1240 demonstrated anti-tumor activity across PD-1- and chemotherapy-resistant patient-derived tumor samples in head and neck, bladder, and lung cancers, with the NKG2A arm identified as a key contributor to this anti-tumor efficacy